Frontlight ResearchEarly access
CompletedPhase 2
Efficacy of MI078 Capsules in Treating Postpartum Depression
Key facts
- Who runs it
- Nanjing Minova Pharmaceutical Co., Ltd.
- Where
- China21 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 72 people enrolled
- Started
- 9 Sept 2024
- Ended
- 7 Aug 2025
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- MI078 capsule dose 1
- MI078 capsule dose 2
- placebo
- Record updated
- 25 June 2026
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Female patients aged 18 to 45 years (inclusive) with a Body Mass Index (BMI) ranging from 18.5 to 37.0 kg/m² (inclusive)
- The patient meets the diagnostic criteria for Major Depressive Disorder (MDD) as defined in the Diagnostic and Statistical Manual of Mental Disorders(DSM-5), based on the investigator's clinical evaluation. The onset of illness must occur between 28 weeks of pregnancy and 4 weeks postpartum (inclusive)
- The patient is within 9 months postpartum during the screening period
- The total score on the HAMD17 is ≥26 during both the screening and baseline periods
- The patient understands and voluntarily agrees to participate in the study, consents to comply with all study requirements, and is able to provide written informed consent prior to the initiation of any study-specific procedures
- The patient is able to communicate effectively with the investigator, is willing and able to adhere to the lifestyle restrictions or requirements specified in the study protocol, and can cooperate fully in completing the trial
Who cannot take part
- Failure to discontinue psychotropic medications for at least 5 half-lives prior to the use of the study drug
- Need for concurrent use of other psychotropic medications, such as antidepressants, antipsychotics, mood stabilizers, and sedative-hypnotics (excluding benzodiazepines), during the trial dosing period
- Current diagnosis of another mental disorder according to DSM-5 criteria, as assessed by the investigator
- History of bipolar disorder, schizophrenia, and/or schizoaffective disorder
- History of sleep apnea
- Presence of suicidal ideation/intent, or a score >3 on Item 3 (suicide) of the HAMD17, or a response of "yes" to Item 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) within the past 6 months, or a history of suicidal behavior within the past year
- Meeting the diagnostic criteria for treatment-resistant depression
- Continuous use of therapeutic doses of antidepressants for more than 14 days during the current episode
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a multicenter, randomized, double-blind, placebo-controlled trial. It includes three groups. Each group will enroll 24 participants. The trial aims todetermine: To evaluate the efficacy of MI078 capsules in treating postpartum depression and to explore the optimal dosing regimen for MI078 capsules.
Read full original descriptionShow less
To assess the safety of MI078 capsules in postpartum depression patients.
The 3 groups in the trial
- MI078 capsule dose 1Treatment being tested
- MI078 capsule dose 2Treatment being tested
- placeboPlacebo, for comparison
Placebo of MI078 capsules
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of MI078 Capsule in Patients With Postpartum Depression
- Record updated
- 25 June 2026